You searched for: deferiprone (Engelska - Estniska)

deferiprone
deferiproon

ferriprox deferiprone
ferriprox deferiproon

the active substance is deferiprone.
toimeaine on deferiproon.

one tablet contains 500 mg deferiprone
Üks tablett sisaldab 500 mg deferiprooni

each tablet contains 500 mg deferiprone.
iga tablett sisaldab toimeainena 500 mg deferiprooni.

ferriprox 100 mg/ml oral solution deferiprone
ferriprox 100 mg/ml suukaudne lahusdeferiproon

deferiprone is the active substance in ferriprox.
ferriprox' i toimeaine on deferiproon.

ferriprox 500 mg film-coated tablets deferiprone
ferriprox 500 mg õhukese polümeerikilega kaetud tabletid deferiproon

each ml of oral solution contains 100 mg deferiprone.
Üks milliliiter suukaudset lahust sisaldab 100 mg deferiprooni.

deferiprone is metabolised predominantly to a glucuronide conjugate.
deferiproon metaboliseerub enamjaolt glükuroniidkonjugaatideks.

deferiprone must not be used by breast-feeding mothers.
deferiprooni ei tohi kasutada imetamise ajal.

the neurological disorders progressively regressed after deferiprone discontinuation.
neuroloogilised häired taandusid järk-järgult pärast deferiproonravi lõpetamist.

deferiprone has been shown to cause neutropenia, including agranulocytosis.
on tõestatud, et deferiproon põhjustab neutropeeniat ja agranulotsütoosi.

ferriprox is a medicine that contains the active substance deferiprone.
ferriprox on ravim, mis sisaldab toimeainena deferiprooni.

important safety reminders for patients taking ferriprox (deferiprone)
oluline ohutusalane meelespea ferriproxi (deferiprooni) kasutavatele patsientidele

treatment with deferiprone should not be initiated if the patient is neutropenic.
patsientidele, kellel on diagnoositud neutropeenia, ei tohiks määrata deferiproonravi.

in one study of two-year duration deferiprone was compared to deferoxamine.
Ühes uuringus, mis vältas 2 aastat, võrreldi deferiprooni deferoksamiiniga.

low plasma zinc levels have been associated with deferiprone in a minority of patients.
Üksikutel patsientidel on deferiproonraviga seostatud plasma tsingisisalduse langust.

the safety of concurrent use of deferiprone and vitamin c has not been formally studied.
deferiprooni ja vitamiin c samaaegse kasutamise ohutust ei ole uuritud.

peak serum concentrations of the glucuronide occur 2 to 3 hours after administration of deferiprone.
glükuroniidi maksimaalne kontsentratsioon seerumis saabub 2 - 3 tundi pärast deferiprooni manustamist.